TY - JOUR
T1 - Investigation of Antimicrobial Activity and Biocompatibility of Biogenic Silver Nanoparticles Synthesized using Syzigyum cymosum Extract
AU - Mahmud, Kazi Mustafa
AU - Hossain, Md Monir
AU - Polash, Shakil Ahmed
AU - Takikawa, Masato
AU - Shakil, Md Salman
AU - Uddin, Md Forhad
AU - Alam, Morshed
AU - Ali Khan Shawan, Mohammad Mahfuz
AU - Saha, Tanushree
AU - Takeoka, Shinji
AU - Hasan, Md Ashraful
AU - Sarker, Satya Ranjan
N1 - Funding Information:
The project was partially supported by Jahangirnagar University research grant 2018, Govt. Of Bangladesh. The authors thank the Wazed Mia Science Research Centre (WMSRC), Jahangirnagar University, for allowing their facilities to characterize the nanoparticles. The authors also thank the Waseda University Central Instrument Facility, Tokyo, Japan, for allowing their comprehensive facilities and services.
Publisher Copyright:
© 2022 American Chemical Society.
PY - 2022/8/9
Y1 - 2022/8/9
N2 - Nanotherapeutics has emerged as the most sought after approach to tackle the menace of drug-resistant pathogenic bacteria. Among others, biogenic silver nanoparticles (bAgNPs) synthesized using medicinal plant extracts demonstrate promising antibacterial propensity with excellent biocompatibility. Herein, bAgNPs were synthesized through the green chemistry approach using Syzygium cymosum leaf extract as a reducing agent at different pH values (i.e., 5, 7, 8, and 10). The average size of bAgNPs synthesized at pH 5, 7, 8, and 10 was 23.3, 21.3, 17.2, and 35.3 nm, respectively, and all the nanoparticles were negatively charged. Their antibacterial potential was investigated against Bacillus subtilis, Escherichia coli DH5α, E. coli K12, enteropathogenic E. coli, and Salmonella typhi. The highest antibacterial activity was exhibited by bAgNPs synthesized at pH 8 against all the tested bacterial strains, which can be attributed to their small size and greater surface area to volume ratio. The bAgNPs demonstrated the highest zone of inhibition (29.5 ± 0.8 mm) against B. subtilis through oxidation of membrane fatty acids that resulted in the formation of the malondialdehyde-thiobarbituric acid (MDA-TBA) adduct. However, bAgNPs demonstrated excellent hemocompatibility with rat and human red blood cells. Biogenic AgNPs synthesized at pH 8 also exhibited biocompatibility in terms of liver and kidney function biomarkers. Furthermore, hematoxylin and eosin staining of the tissue sections of vital organs (i.e., liver, kidneys, lungs, heart, spleen, and brain) also confirmed the biocompatibility of bAgNPs.
AB - Nanotherapeutics has emerged as the most sought after approach to tackle the menace of drug-resistant pathogenic bacteria. Among others, biogenic silver nanoparticles (bAgNPs) synthesized using medicinal plant extracts demonstrate promising antibacterial propensity with excellent biocompatibility. Herein, bAgNPs were synthesized through the green chemistry approach using Syzygium cymosum leaf extract as a reducing agent at different pH values (i.e., 5, 7, 8, and 10). The average size of bAgNPs synthesized at pH 5, 7, 8, and 10 was 23.3, 21.3, 17.2, and 35.3 nm, respectively, and all the nanoparticles were negatively charged. Their antibacterial potential was investigated against Bacillus subtilis, Escherichia coli DH5α, E. coli K12, enteropathogenic E. coli, and Salmonella typhi. The highest antibacterial activity was exhibited by bAgNPs synthesized at pH 8 against all the tested bacterial strains, which can be attributed to their small size and greater surface area to volume ratio. The bAgNPs demonstrated the highest zone of inhibition (29.5 ± 0.8 mm) against B. subtilis through oxidation of membrane fatty acids that resulted in the formation of the malondialdehyde-thiobarbituric acid (MDA-TBA) adduct. However, bAgNPs demonstrated excellent hemocompatibility with rat and human red blood cells. Biogenic AgNPs synthesized at pH 8 also exhibited biocompatibility in terms of liver and kidney function biomarkers. Furthermore, hematoxylin and eosin staining of the tissue sections of vital organs (i.e., liver, kidneys, lungs, heart, spleen, and brain) also confirmed the biocompatibility of bAgNPs.
UR - http://www.scopus.com/inward/record.url?scp=85135876906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135876906&partnerID=8YFLogxK
U2 - 10.1021/acsomega.2c01922
DO - 10.1021/acsomega.2c01922
M3 - Article
AN - SCOPUS:85135876906
SN - 2470-1343
VL - 7
SP - 27216
EP - 27229
JO - ACS Omega
JF - ACS Omega
IS - 31
ER -